Impact of the COVID-19 Epidemic on a Pan-Asian Academic Oncology Clinical Trial

• Eva Segelov,
• Hans Prenen,
• Daphne Day,
• C. Raina Macintyre,
• Estelle Mei Jye Foo,
• Raghib Ali,
• Quanyi Wang,
• Xiaoting Wei,
• Gilberto de Lima Lopes,
• Kefeng Ding,
• Gong Chen,
• John Whay Kuang Chia,
• Han Chong Toh

Affiliations

Eva Segelov

Department of Oncology, Monash Health, and Faculty of Medicine, Monash University, Melbourne, Victoria, Australia

Hans Prenen

Oncology Department, University Hospital Antwerp, Edegem, Belgium

Daphne Day

Department of Oncology, Monash Health, and Faculty of Medicine, Monash University, Melbourne, Victoria, Australia

C. Raina Macintyre

Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia

Estelle Mei Jye Foo

Department of Medical Oncology, National Cancer Centre Singapore, Singapore

Raghib Ali

Public Health Research Centre, New York University, Abu Dhabi, United Arab Emirates

Quanyi Wang

Institute for Infectious Disease and Endemic Disease Control, Beijing Centre for Disease Prevention and Control, Beijing, People’s Republic of China

Xiaoting Wei

Family Health International Clinical, Beijing, People’s Republic of China

Gilberto de Lima Lopes

Global Oncology Program, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL

Kefeng Ding

Department of Surgical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China

Gong Chen

Department of Colorectal Surgery, Sun Yat-Sen University Cancer Centre, Guangzhou, People’s Republic of China

John Whay Kuang Chia

Department of Medical Oncology, National Cancer Centre Singapore, Singapore

Han Chong Toh

Department of Medical Oncology, National Cancer Centre Singapore, Singapore